The added value of contrast-enhanced cardiac magnetic resonance to predict positive genetic testing in clinically suspected Lamin A/C cardiomyopathy. (25th November 2020)

• Record Type: Journal Article
• Authors: Delhommeau, P; Marteau, L; Kyndt, F; Constant Dit Beaufils, A.L; Warin Fresse, K; Serfaty, J.M; Rousseau, O; Karakachoff, M; Conan, E; Clero, S; Le Tourneau, T; Thollet, A; Trochu, J.N; Probst, V; Piriou, N
• Is Part Of: European heart journal. Volume 41:(2020)Supplement 2
• Publication Date: 2020-11-25
• Subjects: Myocardial Disease - Diagnostic Methods; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.12005
• DOI: 10.1093/ehjci/ehaa946.2044
• Languages: English
• ISSNs: 0195-668X

Abstract

Abstract: Background: Lamin A/C cardiomyopathy (CM) is an inherited disease due to LMNA gene mutation with particular phenotype that associates conduction disorders, frequent atrial fibrillation and life-threatening ventricular arrhythmias, with normal or altered ventricular systolic function. Cardiac magnetic resonance (CMR) studies suggest frequent late gadolinium enhancement (LGE) involving septal mid-myocardium. Aims: To assess the added value of CMR to conventional clinical features of Lamin A/C CM for the prediction of a positive LMNA gene testing. Methods: We performed a retrospective monocentric study in all index patients referred for genetic testing for a clinical suspicion of Lamin A/C CM. Clinical, ECG and imaging data including CMR at time of genetic testing in patients with a positive test (LMNA+) and patients without (LMNA-) were compared. The diagnostic performances of relevant parameters for the prediction of a positive LMNA gene testing were analyzed in several logistic regression models. Results: 90 patients were included (55 LMNA+, 35 LMNA-).49% had significant left ventricular (LV) dilatation on echocardiography, 57% had a LV ejection fraction (LVEF)<50%, 46% had a significant left atrial dilatation, and 17% had right ventricular dysfunction. None of these parameters were different comparing LMNA+ and LMNA- patients. LMNA+ patients had significantly more frequent familial history of sudden cardiac death (SCD) or CM. There were no significant differences between LMNA+ and LMNA- patients in terms of conduction disorders, ventricular and supra-ventricular arrhythmias. The only significant difference on ECG was a more frequent abnormal R-wave progression in V1-V3 in LMNA+ patients (87.8% vs 39.4%, p<0.001). 55 patients had a CMR (28/55 LMNA+, 27/35 LMNA-). The main reason for not performing CMR was the presence of cardiac implantable electronic device. LMNA+ patients had significantly more LGE than LMNA- (20/28 (71%) vs 9/27 (33%), p=0.011). The main differences in LGE features between the 2 groups were septal involvement (70% in LMNA+ vs 11% in LMNA-, p=0.005) and mid-myocardium localization (95% vs 44%, p=0.005). In a first logistic regression model without CMR data in all 90 patients, V1-V3 R-wave abnormalities, familial history of SCD and sinus node dysfunction were independent predictors of a positive LMNA gene testing (Sensitivity 89%, specificity 46%, accuracy 72%). A second model in the 55 patients who had a CMR showed better accuracy (85%), mainly driven by increased specificity (81%) with preserved sensitivity (89%). V1-V3 R-wave abnormalities, premature ventricular contractions, non-depressed LVEF and septal LGE predicted positive LMNA gene testing in this model (Septal LGE OR=31, 95% CI 4–715; p=0.005). Conclusion: CMR, particularly septal mid-myocardium LGE, carries good diagnostic accuracy to predict a positive LMNA gene testing in clinically suspected Lamin A/C CM with increased specificity when added to conventional red flags. Funding Acknowledgement: Type of funding source: None